ClinicalTrials.gg
RecruitingNCT07369752Updated Apr 3, 2026

Enhancing Brain And Mental Health Through Breathing Practice

An interventional study of Breathing Intervention in Depressive Disorder, Anxiety and Adolescent, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 319 studies in Depressive Disorder with a site in United States — 38 open to participants now, 44 under way, 2 of them phase 3. Depressive Disorder · United States.

Planned enrollment
186th of 275
40 · median 85
Started
2026
with 10 others
No phase
127 of 319
20 open now
Primary completion
2027-01
later than 12 of 43 live
Registered
312th of 319
by date

Among the 319 studies in Depressive Disorder with a site in United States, this one is the 186th largest by planned enrollment of the 275 interventional ones that give a count, is one of 11 that started in 2026, is one of 127 with no phase, reaches primary completion later than 12 of the 43 other live ones, and was the 312th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

38 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 319 studies in Depressive Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the feasibility of a structured breathing intervention in rural and non-rural adolescents diagnosed with anxiety and depression, recruited from outpatient pediatric and child/adolescent psychiatry clinics.

03

Conditions studied

  • Depressive Disorder
  • Anxiety
  • Adolescent

Keywords

  • Seokmun Hoheup
  • breathing
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents between the ages of 12 and 17 who have been diagnosed with a major depressive disorder (mild or moderate) and/or an anxiety disorder.
  • Participants may have co-occurring mild to moderate alcohol or drug use problems, provided these do not require immediate specialized treatment or crisis intervention.
  • All participants must be receiving care at one of two participating MCHS outpatient psychiatry clinics and may reside in rural area (RUCA code 4-10) or non-rural area.
  • Participants must be able to read and understand English, and both parental or guardian consent and adolescent assent will be required.

Exclusion criteria

Exclusion Criteria:

  • Current suicidal ideation or self-harm behavior requiring immediate clinical intervention
  • Presence of severe psychiatric comorbidities such as psychosis, bipolar disorder, depression with psychotic features, severe alcohol and drug use, or eating disorders.
  • Participants with significant cognitive impairment that would interfere with study participation.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Rural adolescent patients

    Rural and non-rural adolescent patients of Mayo Clinic Health Systems, aged 12 to 17 years, with a clinical diagnosis of mild to moderate anxiety and/or depression will follow a structured breathing practice (Seokmun Hoheup) at least 3 times per week.

    Behavioral: Breathing Intervention

Interventions

  • BehavioralBreathing Intervention

    Participants will follow a structured breathing practice (Seokmun Hoheup) that progresses in incremental steps, beginning with 15 minutes, increasing to 30 minutes, and then to 36 minutes per session over the course of the program.

06

What researchers measure

Primary outcomes

  1. Feasibility of Intervention Measure (FIM) score

    The Feasibility of Intervention Measure (FIM) is a self-reported questionnaire for participants to rate the feasibility of the breathing practice intervention on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)

    Time frame: 4 months

  2. Acceptability of Intervention Measure (AIM) score

    The Acceptability of Intervention Measure (AIM) is a self-reported, 4 question survey, for participants to rate their acceptance of the breathing practice intervention on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)

    Time frame: 4 months

  3. Intervention Appropriateness Measure (IAM) score

    The Intervention Appropriateness Measure (IAM) is a self-reported, 4 question survey, for participants to rate the appropriateness of the breathing practice intervention on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)

    Time frame: 4 months

  4. Recruitment feasibility

    Proportion of eligible adolescents enrolled out of total participants screened

    Time frame: 4 months

  5. Retention feasibility

    Proportion of participants retained through final assessment out of total enrolled

    Time frame: 4 months

Secondary outcomes

  1. System Usability Scale (SUS) score

    Digital usability will be assessed using the System Usability Scale (SUS) tool, a self-reported 10 question survey, for participants to rate the usability of the digital app platform on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)

    Time frame: 4 months

  2. Total number of log-ins

    Total number of times participants logged into the digital app platform

    Time frame: 4 months

  3. Completion rate of assigned breathing practices

    Adherence to breathing practice and intervention engagement will be assessed as the completion rate of assigned sessions as measured by the session attendance logs

    Time frame: 4 months

Other outcomes

  1. Feasibility of collecting physiological data from baseline to 4 months

    Feasibility will be assessed based on data completeness, participant tolerance, and procedural viability from those undergoing fNIRS or MRI testing.

    Time frame: Baseline to 4 months

  2. Feasibility of collecting psychological data

    Feasibility will be assessed by focusing on data completeness of validated mental health measures to include GHQ, GAD, PHQ-9.

    Time frame: Baseline to 4 months

07

Study locations

2 of 2 sites recruiting
  • Mayo Clinic Health System-Albert Lea
    Albert Lea, Minnesota 56007, United States
    Recruiting
    • Marin Nycklemoe · Contact507-255-2814
    • Nicholas Bormann, MD · Principal investigator
  • Mayo Clinic Health System-Eau Claire Clinic
    Eau Claire, Wisconsin 54703, United States
    Recruiting
    • Danielle Boos · Contact715-464-8173
    • Pravesh Sharma, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 11 months is below that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 27, 2026
StartActual
Feb 19, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07369752
Lead sponsor
Mayo Clinic
Responsible party
Pravesh Sharma (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 27, 2026
Start date
Feb 19, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Danielle Boos
Contact
boos.danielle@mayo.edu
715-464-8173
Marin Nycklemoe
Contact
nycklemoe.marin@mayo.edu
507-255-2814
Pravesh Sharma
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion